Who are Ortho-Novum 777's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ortho Tri-Cyclen LO, Ortho Tri Cyclen, Nomegestrol Acetate / Estradiol, Intermittent OC (EE/DROS), Drospirenone and Ethinyl Estradiol tablets, Drospirenone / Estetrol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ortho-novum-777.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ortho-Novum 777 — Competitive Intelligence Brief

Ortho-Novum 777 (Ortho-Novum 777) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triphasic oral contraceptive. Area: Contraception / Gynecology.

phase 3 Triphasic oral contraceptive Progesterone receptor, estrogen receptor Contraception / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Ortho-Novum 777 (Ortho-Novum 777) — NYU Langone Health. Ortho-Novum 777 is a triphasic oral contraceptive that prevents pregnancy through hormonal suppression of ovulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ortho-Novum 777 TARGET	Ortho-Novum 777	NYU Langone Health	phase 3	Triphasic oral contraceptive	Progesterone receptor, estrogen receptor
Ortho Tri-Cyclen LO	Ortho Tri-Cyclen LO	Bristol-Myers Squibb	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Ortho Tri Cyclen	Ortho Tri Cyclen	Virginia Commonwealth University	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Nomegestrol Acetate / Estradiol	Nomegestrol Acetate / Estradiol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, Estrogen receptor
Intermittent OC (EE/DROS)	Intermittent OC (EE/DROS)	University of North Carolina, Chapel Hill	marketed	Oral contraceptive	Progesterone receptor, estrogen receptor
Drospirenone and Ethinyl Estradiol tablets	Drospirenone and Ethinyl Estradiol tablets	Hansoh BioMedical R&D Company	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Drospirenone / Estetrol	Drospirenone / Estetrol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triphasic oral contraceptive class)

NYU Langone Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ortho-Novum 777 — Competitive Intelligence Brief. https://druglandscape.com/ci/ortho-novum-777. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab